Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Oncolytics Biotech Inc T.ONC

Alternate Symbol(s):  ONCY

Oncolytics Biotech Inc. is a clinical-stage biotechnology company. The Company is focused on developing pelareorep, an intravenously delivered immunotherapeutic agent that activates the innate and adaptive immune systems and weakens tumor defense mechanisms. This compound induces anti-cancer immune responses and promotes an inflamed tumor phenotype turning cold tumors hot through innate and adaptive immune responses to treat a variety of cancers. This improves the ability of the immune system to fight cancer, making tumors more susceptible to a broad range of oncology treatments. The Company’s primary focus is to advance its programs in hormone receptor-positive / human epidermal growth factor 2- negative (HR+/HER2-) metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma to registration-enabling clinical studies. In addition, it is exploring opportunities for registrational programs in other gastrointestinal cancers through its GOBLET platform study.


TSX:ONC - Post by User

Comment by Quentin30on Nov 14, 2022 6:35pm
216 Views
Post# 35098228

RE:RE:RE:sad sad sad

RE:RE:RE:sad sad sadThe title was sad Canada, no-one said anything about bad news. I was referring to how the market responded to what is awesome data, it's just that the ONCY team has a knack of turning a golden goose into an undercooked duck.

This should have been a springboard, and yet all we really know is that there is more of the same... aka delay, and we don't have any idea how long... Nothing about timings for approaching the various Regulatory Agencies, nothing about potential regulatory routes for approval.

How about accelerated approval, where are they with potential biomarkers etc?. We got nothing, Nada.

Matt sat there rubbing his eyeballs, looking more like Homer Simpson after each passing minute. Compare his performance to Sam Kulkarni. I want to see real excitement from a CEO, not look at him rubbing his eyes getting ready for bed. He looks to me like he's just bored of it all himself. Does that shout victory is near.?

sheesh... There's nothing new coming down the pipes now until Bracelet-1, so I'd hold back on those yacht orders gentlemen. Perhaps the famous Adlai Nortye will come to our rescue.

 
<< Previous
Bullboard Posts
Next >>